3 results match your criteria: "Doheny Image Reading and Research Lab (DIRRL) - Doheny Eye Institute[Affiliation]"
Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis.
Am J Ophthalmol
August 2025
Doheny Image Reading & Research Lab (DIRRL), Doheny Eye Institute (C.S., G.C., M.A., S.S.), Pasadena, California, USA; Department of Ophthalmology (C.S., G.C., M.A., S.S.), University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA. Electronic address: SSadda@
Objective: To investigate anatomical and functional outcomes in a subset of eyes with neovascular age-related macular degeneration (nAMD) switched from brolucizumab to faricimab in the real-world TRUCKEE study.
Design: Retrospective, multicentric clinical cohort study.
Subjects And Participants: 134 eyes of 108 patients were switched from brolucizumab to faricimab.
Validation of Compensation Algorithm in Healthy Volunteers Using Spectral Domain Optical Coherence Tomography Angiography.
Curr Eye Res
September 2025
Doheny Image Reading and Research Lab (DIRRL) - Doheny Eye Institute, Pasadena, CA, USA.
Purpose: To generate and validate a spectral domain optical coherence tomography angiography (SD-OCTA) device-specific algorithm to compensate for signal attenuation in choriocapillaris (CC) en face OCTA slabs.
Methods: Healthy subjects were imaged on SD-OCTA with a 6 × 6 mm pattern at the Doheny-UCLA Eye Centers. The CC slabs were segmented at the level of the Bruch's membrane using a 16-μm thick slab with the inner boundary located 4 μm below the Bruch's membrane.
Estimating mortality and disability in Peru before the COVID-19 pandemic: a systematic analysis from the Global Burden of the Disease Study 2019.
Front Public Health
July 2023
School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.
Article Synopsis
- Estimating health loss trends in Peru from 1990 to 2019 is crucial for improving healthcare resource allocation and system performance, using data from the Global Burden of Disease study.
- The Peruvian population rose to 33.9 million by 2019, with life expectancy at birth increasing from 69.2 to 80.3 years, largely due to a decrease in under-5 mortality and infectious diseases, while disability-adjusted life-years (DALYs) showed a decline in overall health burden.
- There was a notable shift towards non-communicable diseases as the leading cause of health loss, with major contributors to DALYs in 2019 including neonatal disorders, lower respiratory infections, and lifestyle